Centrient Pharmaceuticals Initiates Patent Litigation in India Against Dalas Biotech Limited

Rotterdam, 1 May 2019 - Centrient Pharmaceuticals (“Centrient”), the global leader in the production and commercialisation of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed a lawsuit against Dalas Biotech Limited (“Dalas”) for patent infringement.

Centrient Pharmaceuticals announced that on April 25, 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 247301. This patent, which is owned by Centrient, describes an enzymatic process for preparing amoxicillin trihydrate having a low free water content. By its complaint, Centrient seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use, sale in India and exportation out of India of Dalas’ active pharmaceutical ingredient containing amoxicillin trihydrate produced by a process that amounts to infringement of Indian Patent No. 247301.

Karl Rotthier, CEO at Centrient said: “After having previously filed patent litigation against Sinopharm Weiqida Pharmaceuticals for patent infringement in India, and the Court granting an injunction since April 2017, Centrient shows that it will continue to rigorously enforce its IP assets worldwide against any additional potential infringers in India or abroad.”